Key result
In experimental heart failure, coronary vasoconstriction to the ET-B agonist sarafotoxin was enhanced (blood flow -31% vs -7% in normal dogs, P<0.001), while the response to ET-1 was attenuated.
Absolute Event Rate: -31% vs -7%
p-value: p=<.001
Experimental heart failure alters coronary endothelin receptor sensitivity, characterized by attenuated ET-1 mediated vasoconstriction and enhanced ET-B mediated vasoconstriction.
No takes yet. Share an insight, caveat, or question.
Should not change clinical practice; leaves open altered endothelin receptor sensitivity in heart failure.
Cannan et al. (1996) studied Experimental congestive heart failure (n=22). ET-1 and sarafotoxin vs. Normal dogs was evaluated on Percent change in coronary blood flow (p=<.001). In experimental heart failure, coronary vasoconstriction to the ET-B agonist sarafotoxin was enhanced (blood flow -31% vs -7% in normal dogs, P<0.001), while the response to ET-1 was attenuated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: